ARCTURUS THERAPEUTICS HLDGS's ticker is ARCT and the CUSIP is 03969T109. A total of 133 filers reported holding ARCTURUS THERAPEUTICS HLDGS in Q1 2022. The put-call ratio across all filers is 0.54 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $519,483 | -11.0% | 20,332 | -0.1% | 0.00% | – |
| Q2 2023 | $583,925 | +147.1% | 20,360 | +106.5% | 0.00% | – |
| Q1 2023 | $236,343 | +48.6% | 9,860 | +5.2% | 0.00% | – |
| Q4 2022 | $159,016 | +21.4% | 9,376 | +5.8% | 0.00% | – |
| Q3 2022 | $131,000 | -39.9% | 8,861 | -36.1% | 0.00% | – |
| Q2 2022 | $218,000 | -35.7% | 13,871 | +10.4% | 0.00% | – |
| Q1 2022 | $339,000 | -27.1% | 12,566 | 0.0% | 0.00% | – |
| Q4 2021 | $465,000 | +1.8% | 12,566 | +31.2% | 0.00% | – |
| Q3 2021 | $457,000 | +148.4% | 9,581 | +76.6% | 0.00% | – |
| Q2 2021 | $184,000 | -25.5% | 5,426 | -9.3% | 0.00% | – |
| Q1 2021 | $247,000 | -5.7% | 5,982 | -1.0% | 0.00% | – |
| Q4 2020 | $262,000 | +14.4% | 6,045 | +12.8% | 0.00% | – |
| Q3 2020 | $229,000 | -12.6% | 5,357 | -4.2% | 0.00% | – |
| Q2 2020 | $262,000 | – | 5,591 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DFPG INVESTMENTS, LLC | 456,390 | $5,541,000 | 3.62% |
| DAFNA Capital Management LLC | 173,914 | $1,890,000 | 0.65% |
| One68 Global Capital, LLC | 19,861 | $216,000 | 0.47% |
| Diametric Capital, LP | 51,982 | $565,000 | 0.41% |
| ARK Investment Management | 1,383,756 | $15,041,000 | 0.38% |
| EAM Investors, LLC | 52,833 | $574,000 | 0.13% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 31,404 | $341,000 | 0.05% |
| Nikko Asset Management Americas, Inc. | 280,548 | $3,050,000 | 0.05% |
| MGO ONE SEVEN LLC | 14,900 | $161,000 | 0.04% |
| Qube Research & Technologies Ltd | 67,702 | $736,000 | 0.02% |